Abstract:The in silico investigation of a novel quinoline‐4‐carboxamide compound involves computational analyses targeting Gram‐positive bacteria. This includes 2D structure modeling, frontier molecular orbital (FMO) and electronic density (ED) simulations, physiochemical and pharmacokinetic profiling, protein‐ligand binding assessment, molecular docking, compound behavior simulations using Gromacs, and principal component analysis (PCA) with the Bio3D package, enhancing understanding of its antibacterial potential. Gram‐positive bacteria represent a significant threat due to their resistance to conventional antibiotics. This study employs computational methods to investigate fusidic acid (FA) derivatives (1–24) as potential antibiotics against Gram‐positive bacteria. Techniques such as density functional theory calculations, molecular docking, and molecular dynamics simulations were utilized to evaluate ligand interactions with target proteins Staphylococcus aureus (S. aureus) elongation factor G (fusA) (2XEX), fusidic acid resistance protein (fusB) (4ADN), and fusidic acid resistance protein (fusC) (2YB5), comparing them to established antibiotics (ceftobiprole, linezolid, vancomycin). Notably, ligand 16 demonstrated a remarkable binding affinity to the S. aureus elongation factor G protein (−8.7 kcal mol−1), closely aligning with both in vitro and in vivo results and outperforming fusidic acid and reference drugs. In silico methods (SwissADME, AdmetSAR, Molinspiration, Molsoft) were used to assess pharmacokinetics and drug‐likeness. Molecular dynamics (MD) simulations confirmed superior S. aureus elongation factor G stability for ligands fusidic acid 1, (Z)‐2‐((3R,4S,8S,9R,10S,11R,13S,14S,16S)‐16‐acetoxy‐3,11‐dihydroxy‐4,8,10,14‐tetramethylhexadecahydro‐17H‐cyclopenta[a]phenanthren‐17‐ylidene)‐5‐cyclohexylidene‐ pentanoic acid (14), (Z)‐2‐((3R,4S,8S,9R,10S,11R,13S, 14S,16S)‐16‐acetoxy‐3,11‐dihydroxy‐4,8,10,14‐tetramethylhexadecahydro‐17H‐cyclopenta[a]phenanthren‐17‐ylidene)‐5cyclohexylidenepentanoic acid (16), and (Z)‐2‐((3R,4S,8S,9R,10S,11R,13S,14S,16S)‐16‐acetoxy‐3,11‐dihydroxy‐4,8,10,14‐tetramethylhexadecahydro‐17H‐cyclopenta[a]phenanthren‐17‐ylidene)‐5‐cyclopentylidenepentanoic acid (17), with ligand 16 exhibiting exceptional stability across various temperatures, especially at human body temperature (310 K). Further molecular dynamics simulations of ligand 16 validated its robust stability and potential to disrupt S. aureus elongation factor G, supporting the docking results and showing strong consistency with in vitro and in vivo findings. Consequently, ligand 16 emerges as a promising candidate for further development as an anti‐Gram‐positive bacterial drug, pending validation through rigorous clinical trials.

Single Atom Editing of the Glycosylated Natural Product Fidaxomicin Improves Acid Stability and Retains Antibiotic Activity

Switching Residues: A Platform for the Synthesis of Fidaxomicin Antibiotics

Unique Aminothiazolyl Coumarins As Potential DNA and Membrane Disruptors Towards Enterococcus Faecalis

Isolation of Fidaxomicin and Shunt Metabolites from Actinoplanes deccanensis

Simulating New Fusidic Acid Derivatives to Target Gram‐Positive Bacteria by Using Computational Methods

Target identification, and optimization of dioxygenated amide derivatives as potent antibacterial agents with FabH inhibitory activity

Genome-based rational engineering of Actinoplanes deccanensis for improving fidaxomicin production and genetic stability

Stepwise increase of fidaxomicin in an engineered heterologous host Streptomyces albus through multi-level metabolic engineering

Modification of Vancomycin Structure to Combat against Emerging Vancomycin Resistance

Expanding the substrate selectivity of the fimsbactin biosynthetic adenylation domain, FbsH

Acridinium-conjugated aromatic heterocycles as highly potent FtsZ inhibitors: Design, synthesis, and biological evaluation

Old fusidane-type antibiotics for new challenges: Chemistry and biology

Design, synthesis and evaluation of novel 9-arylalkyl-10-methylacridinium derivatives as highly potent FtsZ-targeting antibacterial agents

Discovery of Novel Bacterial FabH Inhibitors (Pyrazol-Benzimidazole Amide Derivatives): Design, Synthesis, Bioassay, Molecular Docking and Crystal Structure Determination

Design, Synthesis and Bioactivity Evaluation of Heterocycle-Containing Mono- and Bisphosphonic Acid Compounds

Towards new bioactive fluorine-containing 1,3,4-oxadiazole-amide derivatives: synthesis, antibacterial activity, molecular docking and molecular dynamics simulation study

Alkyl deoxyglycoside-polymyxin combinations against critical priority carbapenem-resistant gram-negative bacteria

Design and synthesis of fascaplysin derivatives as inhibitors of FtsZ with potent antibacterial activity and mechanistic study

Fexinidazole optimization: enhancing anti-leishmanial profile, metabolic stability and hERG safety

A facile and selective derivatization approach on kynurenine-NH 2 in daptomycin, leading to the discovery of hexakynomycin to combat multidrug-resistant Gram-positive pathogens especially daptomycin-resistant bacteria